MTOR and neoplasm: Despite these anti-tumor effects, mTOR inhibitors are rarely given immediately after solid organ transplantation, because they have been associated with the increased incidence of wound healing complications and severe side effects, including peripheral edema and hypertriglyceridemia [94,95].